T-MATE design is not exclusive to specific drug formats or cancer types. The environmentally activated nature of our therapeutics is adaptable to many different cancer types and therapeutic modalities
Driven by a proprietary integrated discovery platform comprising innovative microfluidics-based single-cell screening system, molecular evolution, CADD, AI/ML and beyond
Engineering, iteration, and optimization – from lead generation to candidate T-MATE – broad experience and specific knowledge allow our team to rapidly develop a growing T-MATE repertoire.
Unmatched proprietary T-MATE-specific preclinical in vitro and in vivo validation, PK, and pharmacology studies that ensure the high therapeutic index of our T-MATEs
Safer Therapeutic Strategy
Broadly Applicable
Selectively Activated